246 related articles for article (PubMed ID: 19141783)
1. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
[TBL] [Abstract][Full Text] [Related]
2. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
3. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
4. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
5. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
6. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
[TBL] [Abstract][Full Text] [Related]
8. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
9. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
10. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.
Shen Q; Uray IP; Li Y; Zhang Y; Hill J; Xu XC; Young MR; Gunther EJ; Hilsenbeck SG; Colburn NH; Chodosh LA; Brown PH
Cancer Prev Res (Phila); 2008 Jun; 1(1):45-55. PubMed ID: 19138935
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Sahin O; Wang Q; Brady SW; Ellis K; Wang H; Chang CC; Zhang Q; Priya P; Zhu R; Wong ST; Landis MD; Muller WJ; Esteva FJ; Chang J; Yu D
Cell Res; 2014 May; 24(5):542-59. PubMed ID: 24675532
[TBL] [Abstract][Full Text] [Related]
13. Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
Deng X; Li Q; Hoff J; Novak M; Yang H; Jin H; Erfani SF; Sharma C; Zhou P; Rabinovitz I; Sonnenberg A; Yi Y; Zhou P; Stipp CS; Kaetzel DM; Hemler ME; Yang XH
Neoplasia; 2012 Aug; 14(8):678-89. PubMed ID: 22952421
[TBL] [Abstract][Full Text] [Related]
14. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
15. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
17. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
18. In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk.
Ma Z; Parris AB; Howard EW; Davis M; Cao X; Woods C; Yang X
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32353937
[TBL] [Abstract][Full Text] [Related]
19. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Shen Q; Kim HT; Xu X; Hilsenbeck SG; Bissonnette RP; Lamph WW; Brown PH
Clin Cancer Res; 2007 Oct; 13(20):6224-31. PubMed ID: 17947490
[TBL] [Abstract][Full Text] [Related]
20. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
